Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells

Doxorubicin (Dox) is one of the most commonly used anthracyclines for the treatment of solid and hematological tumors such as B−/T cell acute lymphoblastic leukemia (ALL). Dox compromises topoisomerase II enzyme functionality, thus inducing structural damages during DNA replication and causes direct...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghelli Luserna Di Rorà, Andrea, Ghetti, Martina, Ledda, Lorenzo, Ferrari, Anna, Bocconcelli, Matteo, Padella, Antonella, Napolitano, Roberta, Fontana, Maria Chiara, Liverani, Chiara, Imbrogno, Enrica, Bochicchio, Maria Teresa, Paganelli, Matteo, Robustelli, Valentina, Sanogo, Seydou, Cerchione, Claudio, Fumagalli, Monica, Rondoni, Michela, Imovilli, Annalisa, Musuraca, Gerardo, Martinelli, Giovanni, Simonetti, Giorgia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406704/
https://www.ncbi.nlm.nih.gov/pubmed/34519926
http://dx.doi.org/10.1007/s10565-021-09640-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406704/
https://www.ncbi.nlm.nih.gov/pubmed/34519926
http://dx.doi.org/10.1007/s10565-021-09640-x

Ejemplares similares